Ziekenhuis Oost Limburg — Clinical Trial Site

115 Registered trials

46 Currently recruiting

Organisation

Ziekenhuis Oost Limburg

Location

Genk, Belgium

Identifier

ORG-100041049

Address

Synaps Park 1, 3600, Belgium

Departments

#1001: Cardiology
#1202:Intensive Care
#2104: Cardiology
#3058: Cardiology
#3100: Anesthesiology – Intensive Care
#BE10006: Gastro-Entérologie
3058:Cardiology
4000: Cardiology
7112: Algemene Cardiologie
Anaesthesiology & Intensive Care
Anesthesiologie
Anesthesiology
Anesthesiology and Intensive Care Medicine
Cardiologie
Cardiology
Cardiology study centre G0.03
Center for Reproductive Medicine
Critical care department
Department of Cardiology
Department of Nephrology
Department of Oncology-Hematology-Radiotherapy
Department of Ophthalmology
Emergency medicine, anthesiology and Intensive Care medicine
Gastro-enterology
Gastroenterology
Gastroenterology and hepatology
Gatro-enterologie
Gynaecologie-Verloskunde
gynecology and obstetrics
Hematology
intensive care
Kinderneurologie
N/A
Nefrologie
Neonatal Intensive Care Unit
Neonatology
Nephrology
Oncologie
Oncology
Orthopaedics
Pneumology
Pulmonology
Radiotherapy-Oncology
Respiratoire Oncologie
Respiratory Oncology
Studiecentrum Cardiologie
Studiefons Cardiologie vzw
Surgery
Thoracic vascular surgery
Urologie
Urology

Clinical trials at this site (115)

Search interface

Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended

2023-505903-22-00 Sepsis associated acute kidney injury 4 2024-07-02
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended

2022-502899-23-00 Hepatic Encephalopathy (OHE) 5 2024-04-23
PRAISE-MR trial Ended

2023-506634-70-00 Heart failure with preserved ejection fraction Secunda 6 2024-02-29
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Thrombolysis of symptomatic proximal vein thrombosis 4 2023-12-20
Ilofotase alfa for prevention of renal damage after cardiac surgery Ended

2023-505859-45-00 Risk for renal damage following open heart surgery 4 2023-12-19
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat… Ended

2022-501988-40-00 RSV-associated (subtypes A and B) disease in adults age 5 2023-08-17
A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary… Ended

2022-500746-16-00 Geographic Atrophy 4 2023-08-11
A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended

2022-501470-18-00 Thromboembolic disease 4 2023-06-26
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy Ended

2023-506352-24-00 Non-obstructive Hypertrophic Cardiomyopathy 5 2023-04-13
A multi-center study to evaluate the safety, tolerability and efficacy of TIN816 in patients at risk for acute kidney injury following a car… Ended

2024-511621-64-00 Acute kidney injury 4 2023-01-18
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 5 2022-11-03
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Muscle-Invasive Urothelial Carcinoma of the Bladder 4 2022-01-09
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended

2023-506724-85-00 Migraine 5 2020-11-19
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended

2023-506253-38-00 Migraine 5 2020-11-09
The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial Ended

2024-518736-37-00 Risk of stroke by Atrial Fibrillation 6 2018-01-12
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Hormone receptor-positive, her2-negative advanced/metas 5
Phase 2 study of inhaled SNG001 in mechanically ventilated patients with respiratory virus infection Ended

2024-520375-27-00 Lower respiratory tract viral infections 4